# EDGAR Filing Document

**Accession Number:** 0001595248
**File Stem:** 0000000000-25-009862
**Filing Date:** 2025-9
**Character Count:** 2357
**Document Hash:** dca4222681c2eaef1d913df18311b954
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0000000000-25-009862.hdr.sgml**: 20251121

**ACCESSION NUMBER**: 0000000000-25-009862

**CONFORMED SUBMISSION TYPE**: UPLOAD

**PUBLIC DOCUMENT COUNT**: 2

**FILED AS OF DATE**: 20250911

**FILED FOR**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** Genprex, Inc.
- **CENTRAL INDEX KEY:** 0001595248
- **STANDARD INDUSTRIAL CLASSIFICATION:** PHARMACEUTICAL PREPARATIONS [2834]
- **ORGANIZATION NAME:** 03 Life Sciences
- **EIN:** 900772347
- **STATE OF INCORPORATION:** TX
- **FISCAL YEAR END:** 1231

**FILING VALUES:**
- **FORM TYPE:** UPLOAD
- **SEC FILE NUMBER:** 377-08425

**BUSINESS ADDRESS:**
- **STREET 1:** 1601 TRINITY STREET, BLDG. B
- **STREET 2:** SUITE 3.322
- **CITY:** AUSTIN
- **STATE:** TX
- **ZIP:** 78712
- **BUSINESS PHONE:** 512-537-7997

**MAIL ADDRESS:**
- **STREET 1:** 1601 TRINITY STREET, BLDG. B
- **STREET 2:** SUITE 3.322
- **CITY:** AUSTIN
- **STATE:** TX
- **ZIP:** 78712
**PUBLIC REFERENCE ACCESSION NUMBER**: 0001437749-25-028492

## Text-Extract

```

                                                            September 11, 2025

Ryan Confer
Chief Executive Officer
Genprex, Inc.
3300 Bee Cave Road #650-227
Austin, TX 78746

       Re: Genprex, Inc.
           Draft Registration Statement on Form S-1
           Submitted September 5, 2025
           CIK No. 0001595248
Dear Ryan Confer:

       This is to advise you that we do not intend to review your registration
statement.

        We request that you publicly file your registration statement and
non-public draft
submission on EDGAR at least two business days prior to the requested effective
date and
time. Please refer to Rules 460 and 461 regarding requests for acceleration. We
remind you
that the company and its management are responsible for the accuracy and
adequacy of their
disclosures, notwithstanding any review, comments, action or absence of action
by the staff.

       Please contact Jessica Dickerson at 202-551-8013 with any questions.

                                                            Sincerely,

                                                            Division of
Corporation Finance
                                                            Office of Life
Sciences
cc:   Kate Basmagian, Esq.

```

### Attached PDF Documents

**Attachment 1:** `filename1`

_No text found in this document._